News Releases
In this section
-
Apr 8, 2003Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
RICHMOND, Va., Apr 8, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) today announced that its Chairman and CEO, Geoffrey Allan, Ph.D., will be featured as part of CEOcast's Virtual...
-
Apr 8, 2003Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
RICHMOND, Va., Apr 8, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq: INSM) has initiated a named patient programme in Europe, that will make available the investigational drug...
-
Apr 7, 2003Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
RICHMOND, Va.--(BUSINESS WIRE)--April 7, 2003--Insmed Inc. (NASDAQ:INSM) Insmed Incorporated (Nasdaq: INSM), a leading developer of pharmaceutical products for the treatment of metabolic and...
-
Apr 4, 2003Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
RICHMOND, Va.--(BUSINESS WIRE)--April 4, 2003--Insmed Incorporated (Nasdaq:INSM) reported today that data from recent studies of the Company's proprietary anti-cancer compound, recombinant human...
-
Apr 2, 2003Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
RICHMOND, Va.--(BUSINESS WIRE)--April 2, 2003--Insmed Incorporated (Nasdaq:INSM) announced today that Dr. Geoffrey Allan, Chairman and Chief Executive Officer of Insmed will present to the...
-
Apr 1, 2003Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
RICHMOND, Va.--(BUSINESS WIRE)--April 1, 2003--Insmed, Incorporated (NASDAQ/NMS: INSM), a biopharmaceutical company engaged in the development of drug candidates for the treatment of metabolic...
-
Mar 28, 2003Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
RICHMOND, Va., Mar 28, 2003 (BUSINESS WIRE) -- Insmed, Incorporated (NASDAQ/NMS: INSM), a biopharmaceutical company engaged in the development of drug candidates for the treatment of metabolic...
-
Feb 3, 2003Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
RICHMOND, Va., Feb 3, 2003 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ:INSM) today announced financial results for the year and fourth quarter ended December 31, 2002. Full Year Results Insmed...
-
Jan 29, 2003Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes RICHMOND, Va.--(BUSINESS WIRE)--Jan. 29, 2003--Insmed Incorporated (Nasdaq: INSM)...
-
Jan 28, 2003Insmed Incorporated to Webcast Fourth Quarter Earnings Conference Call; Tuesday, February 4, at 8:00 a.m. ET - 7:00 a.m. CT
RICHMOND, Va.--(BUSINESS WIRE)--Jan. 28, 2003--Insmed Incorporated (Nasdaq:INSM) will announce fourth quarter and full year financial results after market close on Monday, February 3. The Company...
Contact Us
